Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 991-1000 of 1760 for

Edit search filters
  1. Comparison Of In-Home Versus In-Clinic Administration Of Subcutaneous Nivolumab Through Cancer CARE (Connected Access And Remote Expertise) Beyond Walls (CCBW) Program

    Jacksonville, FL

  2. A Study To Evaluate Tucatinib Plus Trastuzumab And Oxaliplatin-based Chemotherapy For HER2+ Gastrointestinal Cancers

    Scottsdale/Phoenix, AZ

  3. Pemigatinib To Treat Metastatic Or Unresectable Colorectal Cancer Harboring FGFR Alterations

    Scottsdale/Phoenix, AZ, Rochester, MN

  4. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study To Test Bone Marrow And Blood In Children With Leukemia That Has Come Back After Treatment Or Is Difficult To Treat - A Leukemia & Lymphoma Society And Children's Oncology Group Study

    Rochester, MN

  5. Study Of Onvansertib In Combination With FOLFIRI And Bevacizumab Versus FOLFIRI And Bevacizumab For Second Line Treatment Of Metastatic Colorectal Cancer In Participants With A Kirsten Rat Sarcoma Virus Gene (KRAS) Or Neuroblastoma-RAS (NRAS) Mutation

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. PRGN-3006 Adoptive Cellular Therapy For CD33-Positive Relapsed Or Refractory AML, MRD Positive AML Or Higher Risk MDS

    Rochester, MN

  7. A Study To Compare Trilaciclib Versus Placebo In Patients Receiving FOLFOXIRI/Bevacizumab For Metastatic Colorectal Cancer

    Rochester, MN

  8. Panitumumab, Regorafenib, Or TAS-102, In Treating Patients With Metastatic And/or Unresectable RAS Wild-Type Colorectal Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. Breast MR

    Rochester, MN

  10. HEADLIGHT: Hypofractionated Proton Therapy For Head And Neck Cancers

    Albert Lea, MN, Scottsdale/Phoenix, AZ, Eau Claire, WI, Jacksonville, FL, La Crosse, WI, Mankato, MN, Rochester, MN

.

Mayo Clinic Footer